ALS Centrum Nederland (UMC Utrecht)

Number of service categories this organization offers.

• ✓1 service category listed

PubMed publications + ClinicalTrials.gov active trials linked to this organization.

• —0 PubMed publications
• —0 active clinical trials

How easy it is for patients and families to reach this organization.

• ✓Has website
• ✓Has phone number
• ✓Has email
• ✓Has street address
• ✓Has map coordinates

Breadth of direct support offered to patients and families.

• —In-person support groups
• —Online support groups
• —Caregiver resources in services
• —Funds or provides home care
• —Children's resources

Percentage of profile fields with information.

• ✓Name
• ✓Type
• ✓Country
• ✓State / region
• ✓Address
• ✓Phone
• ✓Email
• ✓Website
• ✓Mission

Connections to research consortia and ALS networks.

• —Part of a consortia
• —International reach
• —Publishes research
• —Maintains an ALS database
• ✓Mentions a known network (NEALS, ENCALS, TRICALS, etc.)

No community reviews yet — this dimension is excluded from the overall score.

• —No reviews yet

Contact

Mission

National diagnostic center + international ALS research headquarters (the highest-volume ALS center per capita in the world). Lead: **Prof. Dr. Leonard H. van den Berg**, MD, PhD — Professor of Experimental Neurology (recently appointed Clinical Faculty Professor at UMC Utrecht, 2025). Chair of ENCALS. Co-initiator of Project MinE (2014). Founder of TRICALS (2015–2019). Past coordinator of EU grants FP7 Euro-MOTOR (systems biology) and JPND SOPHIA (biomarkers). Corresponding author on dozens of multi-center ALS trials.. Patient volume: 400–500 new ALS diagnoses per year (85–90% of all Dutch ALS/PSMA/PLS patients) One-day diagnostic protocol: virtually all referrals seen within 2 weeks; all diagnostic tests completed same day; diagnostic interview and care plan same afternoon Four research pillars: (1) fundamental research (organoid + organ-on-chip models), (2) genetic research, (3) clinical trials, (4) rehabilitation Active clinical trials (as of 2025-2026): dazucorilant (CORT113176, Corcept), ION363 (FUS-mutation ALS, Ionis), prosetin, MAGNET lithium trial (UNC13A homozygous mutation), reALiSe (ARGX-119), ANQUR (QRL-201), TUDCA phase 3, AMX0035 (Amylyx, post-ALSFRS-R phase 3), pegcetacoplan phase 2, COURAGE-ALS (reldesemtiv), Ravulizumab, DNL343 (Denali), BIIB078 extension (Biogen, C9ORF72), BIIB105 (Ataxin-2 poly-CAG), CARDINALS (Utreloxastat), Verge Genomics VRG50635 phase 1b, Ferrer FNP122 phase 3, Lighthouse 2 (Triumeq phase 3), RT001 phase 2